| Revision as of 23:56, 15 February 2007 edit67.174.199.1 (talk)No edit summary← Previous edit | Revision as of 00:45, 28 February 2007 edit undo207.47.61.234 (talk) →Postulated CausesNext edit → | ||
| Line 26: | Line 26: | ||
| ==Postulated Causes== | ==Postulated Causes== | ||
| Because many patients with SPS have circulating antibodies to the enzyme ] (GAD), an ] cause of the disease has been postulated. However, ] antibodies cannot be the sole cause, as most ] possess anti-GAD antibodies, yet the frequency of SPS among Type I diabetics is 1 in 10000{{ref|levy}}. The GAD protein regions ] recognized by these antibodies may differ in each disease |
Because many patients with SPS have circulating antibodies to the enzyme ] (GAD), an ] cause of the disease has been postulated. However, ] antibodies cannot be the sole cause, as most ] possess anti-GAD antibodies, yet the frequency of SPS among Type I diabetics is 1 in 10000{{ref|levy}}. The GAD protein regions (]) recognized by these antibodies may differ in each disease{{ref|hampe}}. | ||
| ==Treatment== | ==Treatment== | ||
Revision as of 00:45, 28 February 2007
Medical condition| Stiff-person syndrome | |
|---|---|
| Specialty | Neurology  |
| Frequency | 8e-05% |
Stiff person syndrome (SPS) (or occasionally, stiff-man syndrome) is a rare neurologic disorder of unknown etiology.
History
SPS was first described by Moersch and Woltman at the Mayo Clinic in 1956 .
Symptoms and prognosis
Those with the illness experience progressive, fluctuating tonic muscle contractions, particularly the axial musculature. Depression and anxiety are often noted although this may be a result of discomfort due to stiffness, rather than underlying neurochemical abnormalities. MRI detection of GABA in the brain have demonstrated reduced levels in stiff-person syndrome .
Prognosis is variable and there is no reliable predictor of speed and severity of disease onset. Muscle tetany may led to muscle rupture and broken bones, or problems swallowing and breathing in severe cases .
Postulated Causes
Because many patients with SPS have circulating antibodies to the enzyme glutamic acid decarboxylase (GAD), an autoimmune cause of the disease has been postulated. However, GAD antibodies cannot be the sole cause, as most Type I diabetics possess anti-GAD antibodies, yet the frequency of SPS among Type I diabetics is 1 in 10000. The GAD protein regions (epitopes) recognized by these antibodies may differ in each disease.
Treatment
Treatment is mostly palliative with muscle relaxants which enhance GABA production such as benzodiazepines, which lose their effectiveness as the illness progresses. In the absence of double-blind, placebo-controlled class A trials to determine treatment efficacy, some authorities recommend humane trials of immunosuppressive therapy, plasmapheresis or intravenous immunoglobulin infusion.
References
- MOERSCH FP, WOLTMAN HW (1956). "Progressive fluctuating muscular rigidity and spasm ("stiff-man" syndrome); report of a case and some observations in 13 other cases". Mayo Clin Proc. 31 (15): 421–7. PMID 13350379.
- Murinson BB (2004). "Stiff-person syndrome". Neurologist. 10 (3): 131–7. PMID 15140273.
- Hampe C, Hammerle L, Bekris L, Ortqvist E, Kockum I, Rolandsson O, Landin-Olsson M, Törn C, Persson B, Lernmark A (2000). "Recognition of glutamic acid decarboxylase (GAD) by autoantibodies from different GAD antibody-positive phenotypes". J Clin Endocrinol Metab. 85 (12): 4671–9. PMID 11134126.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - Levy L, Dalakas M, Floeter M (1999). "The stiff-person syndrome: an autoimmune disorder affecting neurotransmission of gamma-aminobutyric acid". Ann Intern Med. 131 (7): 522–30. PMID 10507962.
{{cite journal}}: CS1 maint: multiple names: authors list (link)
See also
External links
- Neuroimmunology, The Medical School, Birmingham University - A site about the link between GAD and SPS
- stiffperson at NINDS
- Article at clevelandclinic.org
- Article at eNotes